Take Five: Coronavirus vaccine race is on
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
- Applied Digital (APLD) Tops Q1 EPS by 26c, Beats on Revenue
Novavax (NVAX) Begins Phase 1/2 Clinical Trial of COVID-19 Vaccine
May 26, 2020 5:53 AM EDTNovavax, Inc. (NASDAQ: NVAX) today announced enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVXCoV2373, a stable, prefusion protein made using its proprietary nanoparticle technology. NVXCoV2373 includes Novavax proprietary MatrixM adjuvant to enhance immune responses and stimulate high levels of neutralizing antibodies. Preliminary immunogenicity and safety results from the Phase 1 portion of the trial are expected in July 2020.
Administering our vaccine in the first participants of this clinical trial is a significant achievement, bringing us one step closer toward addressing the... More



